Introduction
HIV RNA levels in untreated chronic infection are known to vary widely, both between and within individuals.
Women have been shown to have lower plasma HIV RNA levels than men [1] [2] [3] . Older people have been shown to have higher HIV RNA levels [4] and a recent paper found that HIV RNA levels increased faster with older age [5] . Some reports have suggested that non-Hispanic blacks have lower HIV RNA levels [6] [7] [8] . A number of host factors have been associated with lower viral load, including human leucocyte antigen (HLA)-B*5701, HLA-B*27, c-c chemokine receptor (CCR) 5 delta-32 heterozygosity and allelic variation in HLA-C and killer-cell immunoglobulinlike receptor (KIR) [9] [10] [11] [12] [13] [14] . These factors are known to be enriched in those rare but highly studied subsets of individuals who durably control HIV to levels below detection using standard assays ('elite' controllers) and those with low but detectable viraemia ('viraemic' controllers). Most of the data gained on these individuals have come from small well-characterized cohorts. From natural history studies, it has been shown that spontaneous control over virus replication occurs at a low prevalence and appears to be established early, at median times of 6.2 to 16.7 months following seroconversion [15] [16] [17] . No study has sought to define the clinical and demographic characteristics of low HIV RNA in a modern cohort of untreated individuals who present without advanced immunodeficiency.
As the recently enrolled Strategic Timing of AntiRetroviral Treatment (START) trial recruited thousands of individuals with early-stage disease across the world, we used this cohort to explore in a more definitive manner those factors associated with low viral load.
Methods
All participants randomized into the START trial were considered for this analysis. As part of the START trial screening process, all participants were to have an HIV RNA assessment within 60 days prior to randomization, and this HIV RNA assessment was taken as the primary endpoint for these analyses. In addition, participants had up to three of their most recent HIV RNA assessments recorded, as well as their maximum documented HIV RNA.
The key focus variables we considered for this analysis were race, and hepatitis B virus (HBV) and hepatitis C virus (HCV) status. Race was considered as a key variable to exploit the heterogenous international recruitment into START. HCV and HBV infections were of particular interest as little has been published on the relationship between these coinfections and untreated HIV RNA levels, and they are both well characterized in the START cohort. Race was coded as black, Hispanic, Asian, white and other. HBV surface antigen status was coded as positive or negative based on a test in the preceding year. Participants without an HBV test in the previous year were recorded as missing status. HCV antibody status was based on the most recent test reported.
Other variables we considered in these analyses included geographical region of randomization, age, sex, mode of HIV exposure, body mass index (BMI), smoking status, current and nadir CD4 cell counts, CD8 cell count, CD4:CD8 ratio, fasting total cholesterol concentration, high-density lipoprotein (HDL) cholesterol concentration, total cholesterol:HDL cholesterol ratio, and receipt of a statin at the time of randomization. HLA-B*5701 was only tested on a minority of START participants, and so was included as a secondary covariate.
Statistical analysis
We summarized overall baseline HIV RNA as the median and interquartile range (IQR), and the proportions of participants with HIV RNA ≤ 50, 51−400, 401−2000, 2001−10 000, 10 001−50 000 and > 50 000 HIV-1 RNA copies/mL. We also summarized the other covariates considered within these baseline HIV RNA categories.
Factors associated with baseline HIV RNA ≤ 50 and ≤ 400 copies/mL were assessed using conditional logistic regression. Because of the strong association between region of randomization and low baseline HIV RNA, which we felt potentially reflected systematic differences between participants or how they were recruited into START from the differing regions, all analyses were stratified by region.
Continuous covariates were split into three groups, using either common cut-offs or tertiles. We developed adjusted risk factor models, considering for inclusion only those covariates that were somewhat associated with baseline HIV RNA in univariate analyses (P < 0.1).
Results
START randomized 4685 participants, of whom three were HIV negative. A further nine participants did not have a baseline HIV RNA assessment and were excluded from all analyses in this paper. The median baseline HIV RNA was 12 750 [interquartile range (IQR) 3000 to 43 600 copies/ mL]. A total of 113 participants (2.4%) had HIV RNA ≤ 50 copies/mL at baseline, and a further 257 (5.5%) had HIV RNA between 51 and 400 copies/mL. Median CD4 count across all participants was 651 cells/μL (IQR 584 to 765 cells/μL). Median time since HIV diagnosis was 1 year (IQR 0.4 to 3 years). Figure 1 shows baseline HIV RNA plotted against the up to three previous HIV RNA results reported. Prerandomization plasma HIV RNA levels were variable within a person, with differences of 1 log 10 not uncommon. Of the 113 participants with baseline HIV RNA ≤ 50 copies/ mL, 30 had one or more previous HIV RNA results reported. At the most recent of these previous HIV RNA results, 18 (60%) were ≤ 50 copies/mL, nine (30%) were 51-400 copies/mL, and three (10%) were > 400 copies/mL. Participant factors are summarized by baseline HIV RNA categories in Table 1 . There is a much higher proportion of participants with low baseline HIV RNA from the African region. Strong associations between HIV RNA levels are also seen for a number of variables.
Factors associated with HIV RNA ≤ 50 copies/mL and ≤ 400 copies/mL are summarized in Tables 2 and 3 , respectively. Factors independently associated with low HIV RNA were largely consistent across the two endpoints, with older age, HIV exposure routes other than male homosexual contact, higher CD4 cell counts, higher CD4:CD8 ratio and higher HDL cholesterol all associated with increased odds of low baseline HIV RNA.
HCV antibody positivity was significantly associated with low HIV RNA in univariate analyses, but only borderline significant when adjusted for other independent predictors. HCV antibody positivity is strongly associated with injecting drug use (IDU), so we also performed an analysis excluding IDUs. The adjusted odds ratio for the association between HCV antibody positivity and HIV RNA ≤ 50 copies/mL excluding IDUs was 2.45 [95% confidence interval (CI) 0.90, 6.67; P = 0.080] and for HIV RNA ≤ 400 copies/mL it was 1.46 (95% CI 0.74, 2.87; P = 0.27).
We did not find an association between race and low HIV RNA in our analyses despite clear differences between the regions. We performed further analyses excluding the African region (where participants are almost entirely black), and adjusted odds ratios comparing white with black participants were 0.51 (95% CI 0.21 to 1.24; P = 0.14) for HIV RNA ≤ 50 copies/mL and 1.01 (95% CI 0.64, 1.61; P = 0.95) for HIV RNA ≤ 400 copies/mL.
In secondary analyses, HLA-B*5701 was also independently associated with an increased odds of HIV RNA ≤ 400 copies/mL. There was no apparent association between HLA-B*5701 and HIV RNA ≤ 50 copies/mL, but only 13 of the 113 participants with HIV RNA ≤ 50 copies/mL had an HLA-B*5701 test performed, of whom only one was HLA-B*5701 positive.
Discussion
We investigated the baseline prevalence and correlates of low HIV RNA levels in the START study, a large global cohort study of untreated individuals without advanced immunodeficiency. In this group of untreated individuals with early-stage disease, we found that HIV exposure categories other than male homosexual contact, higher HDL cholesterol levels, higher CD4 cell counts, and higher CD4:CD8 ratio were associated with low HIV RNA levels. HCV antibody positivity was borderline significantly associated with low HIV RNA. Somewhat surprisingly, we found that older individuals were more likely to have lower viral loads. There was no statistically significant association between race and HBV surface antigen. In secondary analyses, HLA-B*5701 positivity was also associated with HIV RNA ≤ 400 copies/mL, as expected.
We observed a relatively high rate of START participants with low HIV RNA levels, in contrast to previous natural history studies [15] [16] [17] . We believe this probably reflects a shift to lower viral loads at which patients and their providers are in equipoise about the 'when to start' question. It may also in part reflect the eligibility criteria for START, which recruited participants with CD4 cell counts above HIV RNA values are truncated at 50 copies/mL (1.70 log10 copies/mL) and 500 000 copies/mL (5.70 log10 copies/mL). 500 cells/μL. This criterion would tend to reduce recruitment of participants with high viral loads as their CD4 cell counts would fall to ineligible ranges quite quickly. Participants with low HIV RNA levels were also recruited from a number of sites over a period of time, so we believe it is unlikely that this high rate of low HIV RNA is a result of a single laboratory not carrying out the assay correctly for a brief period. Theoretically, it is possible that the high rate of low HIV RNA levels is because some participants were recruited to START while receiving treatment. Although this has been seen in a small minority of participants recruited to other trials [18, 19] , there is only one person in START reported to have taken ART prior to enrolment, and we believe it is unlikely this is more widespread as such participants would not gain anything if randomized to the deferred arm. Female sex has been previously associated with lower viral load in untreated chronic HIV infection [1] [2] [3] . We combined sex and mode of HIV exposure into a single variable because of the large number of men who have sex with men recruited into START, but our results are consistent with these previous results. The mechanisms that might account for this gender effect are not well understood, but some have argued that the hormonal environment in premenopausal women might limit HIV replication. The associations of higher CD4 cell counts and higher CD4:CD8 ratios with low HIV RNA levels were broadly as expected. Low HIV RNA predicts slower CD4 depletion, and so, even within a cohort restricted to participants with high CD4 cell counts, the CD4 cell count association would be expected. Lower CD8 cell counts have also been associated with lower HIV RNA levels. In our analyses, CD4:CD8 ratio was an independent predictor of low HV RNA rather than CD8 cell count itself.
We also found that older age was associated with low baseline HIV RNA. This is at odds with previous studies In adjusted analyses, covariables in bold are included in the final model and are presented adjusted for each other. Other covariables are each presented adjusted for those in the final model. CD4:CD8, CD4 cell count to CD8 cell count ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high-density lipoprotein; HLA, human leucocyte antigen; IDU, injecting drug use; OR, odds ratio; MSM, men who have sex with men. [4, 5] . We feel that this apparent age association probably reflects the way participants were recruited into START. Older persons are probably infected with HIV for longer periods, and indeed in our data there is a positive correlation between age and time since HIV diagnosis (Pearson's rho = 0.27; P < 0.001). As participants needed CD4 cell counts above 500 cells/μL to be eligible for START, persons with longer durations since diagnosis would have generally needed lower HIV RNA levels for their CD4 cell counts to remain elevated in this eligible range. Perhaps one of the most surprising findings in our cohort was the association, albeit of borderline statistical significance, between HCV seropositivity and a low viral load. Other cohort studies have reported a high prevalence of HCV infection in their HIV controllers [20] . Although a number of studies have argued that similar host factors might account for control of both HIV and HCV [20] [21] [22] [23] , this would not readily explain why HCV coinfection predicts HIV control. Our observation needs confirmation in other studies. If it is confirmed, then more mechanistic work to determine if HCV might enhance HIV control (perhaps by acting as a powerful adjuvant to the immune system) might be pursued.
Assessing race in our analyses was difficult, as race was confounded with region, which was also highly confounded with low baseline HIV RNA. We felt that it was important to stratify by region, and this has limited the power of our analyses to identify an effect. We also performed further analyses that excluded the African region, and these also did not identify a significant association. However, our results do not exclude the possibility that a modest association does exist. Non-Hispanic black race has been associated with low viral load in previous studies [6] [7] [8] . Polymorphisms in apolipoprotein 1 (APOL1) are known to explain most of the increased risk of HIVassociated nephropathy and end-stage renal disease in non-Hispanic blacks and have recently been suggested to be associated with low viral load [24] .
We found that lower plasma HIV RNA levels were associated with high HDL cholesterol levels, confirming an observation made in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study, albeit it at lower CD4 counts [25] . The causal pathway for this association is unknown and cannot be assessed in this cross-sectional study. Theoretically, as HIV replication is known to affect lipid metabolism (presumably via its effect on inflammation), it is possible if not likely that the high HDL cholesterol may have been a consequence of lower amounts of HIV replication. It has been proposed that an enzyme lecithin-cholesterol acyltransferase (LCAT) is affected by HIV and the altered activity of LCAT causes low HDL cholesterol in high viraemia [26] .
We did not consider HIV subtype or baseline resistance patterns in our analyses. Subtype will vary by region and could be associated with low HIV RNA levels, another reason supporting stratification of analyses by region. We did not attempt to assess subtype because the majority of START participants did not have genotyping performed. Furthermore, such genotyping would not have been possible in participants with a low viral load, so subtype would have been almost completely missing in the subgroup that formed the focus of this paper. However, subtype and baseline resistance patterns are the focus of a separate START paper in this issue [27] , assessing associations with other covariates.
Strengths of our analyses include the large heterogeneous population recruited into the START trial and the high-quality HIV RNA and risk factor data available. There are, however, limitations. First, this is a cross-sectional study, which makes it impossible to explore the causal pathways among the various associations we identified. Secondly, the study may not be fully generalizable to all untreated adults. To be eligible for recruitment into START, participants had to have high CD4 cell counts and be willing to be randomized to either immediate or deferred antiretroviral therapy. As individuals with very high viral loads may have been less likely to accept randomization, particularly in developed countries, our cohort may be enriched for those with lower viral loads. These issues do potentially limit the generalizability of our findings to broader populations with lower CD4 cell counts.
In conclusion, we found that HIV exposure modes other than male homosexual contact, higher CD4 cell count, higher CD4:CD8 ratio, higher HDL cholesterol and HLA-B*5701 were associated with low HIV RNA levels at baseline in START patients. HCV antibody positivity was surprisingly, albeit borderline statistically significantly, associated with low HIV RNA and requires further research in this and other studies.
The START study is registered at clinicaltrials.gov (NCT00867048).
